Dr. Jacqueline Lui, President of Eagle IP Limited, gave a talk titled “IP Protection Strategies for Drugs” at the Hong Kong Productivity Council for the forum “如何利用防偽技術保護藥品商標及品牌研討會(II)”.
我们的过去活动
Recommended Insights
Can Post Filing Data Overcome Inventive Step in China?
2018年11月19日Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
阅读更多 >
What is the difference between an Invention Patent and a Utility Model Patent?
2021年8月13日There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]
阅读更多 >
Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?
2021年8月19日Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Seminal Cases by the SPC Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for […]
阅读更多 >
CHINA: New Patent Examination Guidelines Now Available for Public Comment
2021年8月4日Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]
阅读更多 >